Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetes Prevention
100%
Lixisenatide
100%
Glucagon-like peptide-1 Receptor (GLP-1R)
85%
Postprandial Glucose
57%
Gastric Emptying
57%
Glucose Excursion
57%
Basal Insulin
28%
Adverse Events
14%
A1 Receptor
14%
Hypoglycemia
14%
Once-daily
14%
Antidiabetic Drugs
14%
Type 2 Diabetic Patients
14%
Glycemic Control
14%
Low Dose Rate
14%
Monotherapy
14%
Receptor Agonist
14%
Nausea
14%
Fasting Plasma Glucose
14%
Lifestyle Modification
14%
Glucagon-like
14%
Dietary Modification
14%
Glucagon Secretion
14%
Insulin Secretion
14%
Expert Opinion
14%
Area Cover
14%
Proteolytic Degradation
14%
Vomiting
14%
GLP-1 Receptor Agonist
14%
Short-acting
14%
Oral Antidiabetics
14%
Sustained Effect
14%
Suitable Target
14%
Welcome
14%
Insulin Glargine
14%
Enhanced Stability
14%
Once-daily Administration
14%
Probe Technology
14%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Lixisenatide
100%
Stomach Emptying
57%
Drug Therapy
28%
Antidiabetic Agent
28%
Glucagon-Like Peptide-1 Agonist
28%
Adverse Event
14%
Lifestyle Modification
14%
Hypoglycemia
14%
Patient with Type 2 Diabetes
14%
Body Weight
14%
Clinical Study
14%
Insulin Release
14%
Glucagon Release
14%
Glycemic Control
14%
Monotherapy
14%
Nausea and Vomiting
14%
Insulin Glargine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Lixisenatide
100%
Antidiabetic Agent
28%
Glucagon Like Peptide 1 Receptor Agonist
28%
Adverse Event
14%
Hypoglycemia
14%
Monotherapy
14%
Nausea and Vomiting
14%
Clinical Study
14%
Glucagon
14%
Insulin Glargine
14%